Nadine MuskatelTungMD

Physician

Dr. Tung is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Beth Israel Hospital
330 Brookline Avenue
Boston, MA 02215
Phone+1 617-667-7081

Fax+1 617-975-5665

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1987
Harvard Medical SchoolClass of 1984

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 2
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Recruiting
Phase 2
Roles: Contact, Principal Investigator
ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16
Recruiting
Phase 2
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy Start of enrollment: 2020 Mar 13
Recruiting
Phase 2
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) Start of enrollment: 2020 Jul 02
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer Start of enrollment: 2021 Jan 11
Recruiting
Phase 2
Roles: Principal Investigator, Contact
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Start of enrollment: 2018 Jun 21
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Olaparib In Metastatic Breast Cancer Start of enrollment: 2018 Apr 01
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

PubMed

714 citations
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver, Andrea L. Richardson, Aron Charles Eklund, Zhigang C. Wang, Zoltan Szallasi
Journal of Clinical Oncology. 2010-03-01
1008 citations
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek, Tara M. Friebel, Christian F. Singer, D. Gareth Evans, Henry T. Lynch
JAMA. 2010-09-01
266 citations
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Kelly A. Metcalfe, Daphna Birenbaum-Carmeli, Jan Lubinski, Jacek Gronwald, Henry T. Lynch
International Journal of Cancer. 2008-05-01

REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast CancerMay 14th, 2024